The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
No posts for 4 days. Has everyone jumped ship?
Is anyone else waiting for either: an RNS saying we have given up on the lft: expect a drop to 20’s with a gradual recover to 30-40’s. Or without news just a slow decline to the 30-40’s. That’s when I’ll consider buying back in for the Tx. I’m realistic that at this stage chances of success is perhaps 10% but worth a gamble. It’s the same with any new pharma product.
There is no typical length of time it takes for a drug to be tested and approved. It might take 10 to 15 years or more to complete all 3 phases of clinical trials before the licensing stage.
Yes we have mhra approval and have started on the long journey. But before covid excitement started the sp was 20p. This is the baseline from which all Tx news would take off. When mrha approval was announced the sp moved up just shy of 100%. So without Dx we could be looking at the sp settling around 40p.
As we have all discovered British diagnostics doesn’t have the necessary lobbying power to gets itself noticed by governments, hence no contracts. Anyone who has witnessed what goes on behind the scenes will understand that simply being the best in terms of a test and facilities isn’t good enough.
Interesting article looking at the chances for a new drug making it to market. Oncology appears to be a difficult field with only 3.4% making it.
https://www.nuventra.com/resources/blog/why-do-clinical-trials-fail/
Based upon their analysis, the overall probability of success (POS) for industry-sponsored drugs entering Phase 1 trials to obtain FDA approval was 13.8%. This number was slightly higher than other recent analyses of similar data sets (Thomas 2016; Hay 2014). Not surprisingly, the highest POS was for drugs moving from Phase 1 to Phase 2 (66.4%), while the lowest POS was for drugs moving from Phase 2 to Phase 3 (58.3%).
Interestingly, the POS to get from Phase 3 to approval was only 59.0%. This means that around 2 out of every 5 drugs that reach Phase 3 “confirmatory” trials still fail to win approval for the indication being investigated. Even when looking only at lead indications, still about 30% of drugs in Phase 3 fail to reach approval.
When viewed by therapeutic area, the authors observed overall POS values that ranged from 3.4% for oncology to 33.4% for vaccines. Oncology, which is a notoriously difficult area of drug development, was the only therapeutic area with a POS <15%. When oncology was excluded from the assessment, the overall POS increased from 13.8% to 20.9%.
So many predictions. All we will see is the same rise and fall we have all all witnessed when the sp was in the 120’s. Everyone getting excited when it rises to the mid 120’s only to fall back to the teens. We are all patiently waiting for news on the therapeutic arm.
“ OMFG, I really hope that Indian Doc is wrong or this is going to be a **** show v shortly. Thanks for posting Fruits”
Yes he’s got it wrong. The origin of the US report is Newsweek.
It’s 500% not 500x more infectious.
What it means:
If an investigational agent shows promise by demonstrating safety and reducing COVD-19 symptoms through 28 days following administration, the ACTIV-2 trial is designed to expand seamlessly from a Phase 2 to a Phase 3 study to gather additional critical data from a larger pool of volunteers without delay.
It works like a flower bud’: The new Covid test that could end the need to self-isolate
Telegraph today:
The company has this week partnered with Abingdon Health, the London-listed test-maker, which previously built fertility tracking tests and developed Covid antibody tests.
100 million tests a year
Abingdon will be making the tests for Vatic under a deal which initially will see it making as many as two million tests a month, but could increase to 100 million tests every year.
Published yesterday so new info:
ORIGINAL ARTICLE
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
List of authors.
Ann R. Falsey, M.D., Magdalena E. Sobieszczyk, M.D., M.P.H., Ian Hirsch, Ph.D., Stephanie Sproule, M.Math., et al., for the AstraZeneca AZD1222 Clinical Study Group*
September 29, 2021
DOI: 10.1056/NEJMoa2105290